insulin aspart
Fiasp, NovoMix, NovoRapid · ATC code A10AB05
Brand names: Fiasp, NovoMix, NovoRapid, Fiasp® Flextouch®, Fiasp® Penfill®
- Key facts
- Active substance
- insulin aspart
- Drug class
- Insulin analog
- ATC code
- A10AB05
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Fiasp 100 units/mL FlexTouch solution for injection in pre-filled pen / Fiasp 100 units/mL Penfill solution for injection in cartridge / Fiasp 100 units/mL solution for injection in vial · NovoMix 30 Penfill 100 units/ml suspension for injection in cartridge / NovoMix 30 FlexPen 100 units/ml suspension for injection in pre-filled pen · NovoMix 50 Penfill 100 units/ml suspension for injection in cartridge / NovoMix 50 FlexPen 100 units/ml suspension for injection in pre-filled pen · NovoRapid 100 units/ml solution for injection in vial / NovoRapid Penfill 100 units/ml solution for injection in cartridge / NovoRapid FlexPen 100 units/ml solution for injection in pre-filled pen
- Marketing authorisation holder
- Novo Nordisk A/S
- Information as of
- 2026-10-27
Key facts
Insulin aspart is a rapid-acting insulin analogue. It is used as NovoRapid, as Fiasp (mealtime insulin) and as the premixed NovoMix 30/50 for the treatment of diabetes mellitus.
What it is used for
- NovoRapid and Fiasp: diabetes mellitus in adults, adolescents and children aged 1 year and above
- NovoMix 30: diabetes mellitus from 10 years of age
- NovoMix 50: diabetes mellitus in adults
Dosing
- Dosing is individual; blood glucose monitoring and dose adjustment are recommended
- NovoRapid: requirement usually 0.5 to 1.0 unit/kg/day; in basal-bolus regimens 50–70% as NovoRapid, with basal insulin
- Fiasp: up to 2 minutes before the start of the meal, optionally up to 20 minutes after; type 2: initial dose 4 units at one or more meals
- NovoMix 30 in type 2: start with 6 units at breakfast and 6 units at dinner, or 12 units once daily at dinner
- NovoMix 30 and 50 not given intravenously or in insulin pumps
- In renal or hepatic impairment and in the elderly, intensified monitoring and individual dose adjustment
Contraindications
- Hypersensitivity to the active substance or any of the excipients
Important warnings
- Hypoglycaemia with omitted meals, unplanned exercise or too high a dose; warning symptoms may change
- Fiasp: hypoglycaemia may occur earlier due to the earlier onset of action
- Hyperglycaemia and diabetic ketoacidosis with inadequate dosing or discontinuation, especially in type 1
- NovoMix: intravenous use may cause severe hypoglycaemia
- Seek medical advice before travelling across time zones
Side effects
- Most frequent: hypoglycaemia
- At treatment start: refraction anomalies, oedema, injection site reactions
- Lipodystrophy, cutaneous amyloidosis, allergic skin reactions, rarely anaphylaxis
- Temporary worsening of diabetic retinopathy with abrupt glucose improvement; acute painful neuropathy
Interactions
- Reduce insulin requirement: oral antidiabetics, GLP-1 agonists, MAOIs, beta-blockers, ACE inhibitors, salicylates, anabolic steroids, sulphonamides
- Increase insulin requirement: oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone, danazol
- Beta-blockers may mask hypoglycaemia; alcohol may intensify or reduce the effect
Pregnancy and breastfeeding
- NovoRapid and Fiasp can be used in pregnancy; experience with NovoMix is limited
- Insulin requirements usually fall in the first trimester and rise in the second and third
Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- Dazparda · biosimilarGan & Lee Pharmaceuticals Europe GmbH · EMEA/H/C/006187
- FiaspNovo Nordisk A/S · EMEA/H/C/004046
- Insulin aspart Sanofi · biosimilarSanofi Winthrop Industrie · EMEA/H/C/005033
- Kirsty (previously Kixelle) · biosimilarBiosimilar Collaborations Ireland Limited · EMEA/H/C/004965
- NovoMixNovo Nordisk A/S · EMEA/H/C/000308
- NovoRapidNovo Nordisk A/S · EMEA/H/C/000258
Source: European Medicines Agency (EMA), product information
Turkey
- Fiasp® Flextouch®NOVO NORDİSK SAĞLIK ÜRÜNLERİ TİC LTD. ŞTİ. · 3 register entries
- Fiasp® Penfill®NOVO NORDİSK SAĞLIK ÜRÜNLERİ TİC LTD. ŞTİ. · 2 register entries
- NovomixNOVO NORDİSK SAĞLIK ÜRÜNLERİ TİC LTD. ŞTİ. · 2 register entries
- NovorapidNOVO NORDİSK SAĞLIK ÜRÜNLERİ TİC LTD. ŞTİ. · 3 register entries
Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16
Brand names in 3 more European countries
- Iceland
- Dazparda, Fiasp, Insulin Aspart Sanofi, Kirsty, Novomix, Novorapid
- Liechtenstein
- Dazparda, Insulin Aspart Sanofi, Kirsty
- Norway
- Dazparda, Fiasp, Insulin Aspart Sanofi, Kirsty, Novomix, Novorapid
EMA – Article 57 product data (EU/EEA), 2026-10-28
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Other substances in the same group
Related calculators
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Fiasp – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/fiasp-epar-product-information_en.pdf
- European Medicines Agency. NovoMix – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/novomix-epar-product-information_en.pdf
- European Medicines Agency. NovoRapid – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/novorapid-epar-product-information_en.pdf
- TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
- Wikidata (CC0): ATC A10AB.
Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.